Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 22 | 2024 | 255 | 9.670 |
Why?
|
Early Detection of Cancer | 17 | 2024 | 501 | 3.650 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2021 | 244 | 3.550 |
Why?
|
Telemedicine | 7 | 2023 | 182 | 2.690 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 5 | 2023 | 50 | 2.660 |
Why?
|
Neoplasms | 12 | 2023 | 438 | 2.590 |
Why?
|
Health Care Costs | 8 | 2019 | 228 | 2.330 |
Why?
|
Breast Neoplasms | 11 | 2021 | 949 | 2.310 |
Why?
|
Humans | 96 | 2024 | 17611 | 2.240 |
Why?
|
Colorectal Neoplasms | 10 | 2022 | 613 | 1.790 |
Why?
|
Aged | 40 | 2023 | 6095 | 1.650 |
Why?
|
Electronic Health Records | 9 | 2024 | 681 | 1.620 |
Why?
|
Delivery of Health Care | 8 | 2023 | 415 | 1.510 |
Why?
|
Neoplasm Staging | 10 | 2019 | 325 | 1.440 |
Why?
|
Middle Aged | 46 | 2023 | 7911 | 1.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2016 | 44 | 1.370 |
Why?
|
Health Maintenance Organizations | 12 | 2014 | 417 | 1.330 |
Why?
|
Female | 49 | 2024 | 12608 | 1.320 |
Why?
|
Retrospective Studies | 22 | 2024 | 2447 | 1.300 |
Why?
|
Adult | 34 | 2023 | 7598 | 1.260 |
Why?
|
Male | 46 | 2024 | 10008 | 1.260 |
Why?
|
United States | 28 | 2023 | 3956 | 1.180 |
Why?
|
Algorithms | 5 | 2018 | 233 | 1.180 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 59 | 1.170 |
Why?
|
Aged, 80 and over | 19 | 2023 | 1900 | 1.170 |
Why?
|
Internet | 6 | 2014 | 231 | 1.050 |
Why?
|
Deductibles and Coinsurance | 2 | 2023 | 30 | 0.980 |
Why?
|
Angiogenesis Inhibitors | 2 | 2015 | 6 | 0.970 |
Why?
|
Mass Screening | 7 | 2024 | 661 | 0.930 |
Why?
|
Malnutrition | 1 | 2023 | 2 | 0.890 |
Why?
|
Clinical Coding | 3 | 2018 | 11 | 0.880 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2011 | 748 | 0.820 |
Why?
|
Colorado | 14 | 2023 | 163 | 0.810 |
Why?
|
Population Dynamics | 1 | 2021 | 6 | 0.790 |
Why?
|
Medicare | 7 | 2023 | 202 | 0.780 |
Why?
|
Self Care | 3 | 2012 | 163 | 0.770 |
Why?
|
Preventive Medicine | 1 | 2021 | 24 | 0.770 |
Why?
|
Bevacizumab | 3 | 2016 | 8 | 0.760 |
Why?
|
Pandemics | 8 | 2023 | 287 | 0.760 |
Why?
|
Smoking Cessation | 6 | 2009 | 193 | 0.750 |
Why?
|
Natural Language Processing | 1 | 2021 | 57 | 0.730 |
Why?
|
Risk Reduction Behavior | 2 | 2011 | 108 | 0.710 |
Why?
|
Health Services | 3 | 2018 | 112 | 0.710 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 2 | 0.680 |
Why?
|
Models, Organizational | 1 | 2019 | 55 | 0.680 |
Why?
|
Electronic Mail | 3 | 2021 | 51 | 0.680 |
Why?
|
Melanoma | 1 | 2019 | 35 | 0.650 |
Why?
|
Patient Selection | 5 | 2013 | 190 | 0.640 |
Why?
|
Smoking | 4 | 2023 | 483 | 0.640 |
Why?
|
Cohort Studies | 11 | 2022 | 2570 | 0.630 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 322 | 0.620 |
Why?
|
Skin Neoplasms | 1 | 2019 | 57 | 0.620 |
Why?
|
Managed Care Programs | 5 | 2009 | 325 | 0.620 |
Why?
|
Diagnostic Imaging | 3 | 2017 | 45 | 0.610 |
Why?
|
Insurance Claim Review | 1 | 2018 | 61 | 0.600 |
Why?
|
Costs and Cost Analysis | 5 | 2018 | 80 | 0.600 |
Why?
|
Prostatic Neoplasms | 5 | 2022 | 262 | 0.600 |
Why?
|
Primary Health Care | 8 | 2024 | 766 | 0.590 |
Why?
|
Patient Care Management | 1 | 2017 | 30 | 0.590 |
Why?
|
Population Surveillance | 6 | 2017 | 263 | 0.580 |
Why?
|
Health Promotion | 3 | 2009 | 280 | 0.540 |
Why?
|
Renin-Angiotensin System | 1 | 2016 | 17 | 0.540 |
Why?
|
Public Health Informatics | 3 | 2005 | 7 | 0.540 |
Why?
|
Health Behavior | 4 | 2014 | 359 | 0.530 |
Why?
|
Obesity | 4 | 2023 | 837 | 0.520 |
Why?
|
Weight Loss | 3 | 2013 | 303 | 0.510 |
Why?
|
Young Adult | 10 | 2019 | 2427 | 0.490 |
Why?
|
SEER Program | 5 | 2019 | 91 | 0.490 |
Why?
|
Treatment Outcome | 9 | 2016 | 1259 | 0.480 |
Why?
|
Follow-Up Studies | 6 | 2018 | 1210 | 0.470 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2014 | 24 | 0.460 |
Why?
|
Tomography, X-Ray Computed | 5 | 2024 | 205 | 0.460 |
Why?
|
Hispanic Americans | 3 | 2011 | 404 | 0.460 |
Why?
|
Hormones | 1 | 2013 | 14 | 0.450 |
Why?
|
Drug Therapy | 1 | 2013 | 18 | 0.450 |
Why?
|
Lung | 3 | 2024 | 62 | 0.440 |
Why?
|
Firearms | 2 | 2024 | 32 | 0.430 |
Why?
|
Influenza, Human | 3 | 2015 | 263 | 0.430 |
Why?
|
Physical Fitness | 1 | 2013 | 73 | 0.430 |
Why?
|
Induction Chemotherapy | 1 | 2012 | 3 | 0.420 |
Why?
|
Patient Education as Topic | 5 | 2010 | 211 | 0.420 |
Why?
|
Community Health Centers | 1 | 2013 | 64 | 0.420 |
Why?
|
Weight Reduction Programs | 1 | 2013 | 52 | 0.410 |
Why?
|
Registries | 6 | 2018 | 471 | 0.400 |
Why?
|
Health Personnel | 3 | 2021 | 124 | 0.400 |
Why?
|
Asthma | 3 | 2021 | 385 | 0.390 |
Why?
|
Ambulatory Care | 3 | 2023 | 244 | 0.390 |
Why?
|
Age Factors | 4 | 2019 | 917 | 0.390 |
Why?
|
Behavior Therapy | 2 | 2012 | 146 | 0.380 |
Why?
|
Databases, Factual | 3 | 2018 | 309 | 0.370 |
Why?
|
Disease Outbreaks | 3 | 2005 | 36 | 0.370 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2019 | 531 | 0.360 |
Why?
|
Adolescent | 10 | 2024 | 3651 | 0.360 |
Why?
|
Bioterrorism | 3 | 2005 | 5 | 0.350 |
Why?
|
Nutrition Therapy | 1 | 2009 | 4 | 0.340 |
Why?
|
Nutrition Assessment | 1 | 2009 | 26 | 0.340 |
Why?
|
Diabetic Neuropathies | 1 | 2009 | 13 | 0.330 |
Why?
|
Cost-Benefit Analysis | 3 | 2015 | 250 | 0.330 |
Why?
|
Behavioral Medicine | 1 | 2009 | 4 | 0.330 |
Why?
|
Reproducibility of Results | 4 | 2017 | 381 | 0.330 |
Why?
|
Health Status Indicators | 3 | 2018 | 64 | 0.330 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 630 | 0.320 |
Why?
|
Program Evaluation | 2 | 2009 | 223 | 0.320 |
Why?
|
Life Style | 2 | 2011 | 332 | 0.320 |
Why?
|
Cost of Illness | 2 | 2019 | 92 | 0.310 |
Why?
|
Advertising as Topic | 2 | 2005 | 23 | 0.310 |
Why?
|
Prevalence | 3 | 2023 | 884 | 0.310 |
Why?
|
Influenza Vaccines | 2 | 2015 | 267 | 0.300 |
Why?
|
Colonic Neoplasms | 2 | 2019 | 155 | 0.300 |
Why?
|
Genetic Testing | 2 | 2005 | 70 | 0.300 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2018 | 7 | 0.300 |
Why?
|
Prostatic Hyperplasia | 2 | 2018 | 24 | 0.290 |
Why?
|
Time Factors | 6 | 2021 | 1086 | 0.280 |
Why?
|
Patient Compliance | 3 | 2023 | 298 | 0.280 |
Why?
|
Incidence | 2 | 2022 | 1255 | 0.280 |
Why?
|
Insurance, Health | 3 | 2019 | 181 | 0.270 |
Why?
|
Low Back Pain | 1 | 2006 | 54 | 0.270 |
Why?
|
Economics, Medical | 2 | 2022 | 4 | 0.270 |
Why?
|
Guideline Adherence | 3 | 2019 | 155 | 0.260 |
Why?
|
Carboplatin | 2 | 2016 | 7 | 0.260 |
Why?
|
Paclitaxel | 2 | 2016 | 9 | 0.260 |
Why?
|
Prognosis | 2 | 2018 | 606 | 0.250 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 197 | 0.250 |
Why?
|
Body Mass Index | 3 | 2023 | 958 | 0.250 |
Why?
|
Survival Rate | 2 | 2016 | 260 | 0.240 |
Why?
|
Medical Records Systems, Computerized | 5 | 2013 | 85 | 0.240 |
Why?
|
Immunization Schedule | 1 | 2005 | 122 | 0.240 |
Why?
|
Wounds, Gunshot | 1 | 2024 | 19 | 0.240 |
Why?
|
Research Design | 5 | 2023 | 374 | 0.240 |
Why?
|
Forecasting | 2 | 2022 | 75 | 0.230 |
Why?
|
Fee-for-Service Plans | 2 | 2014 | 24 | 0.220 |
Why?
|
Immunotherapy | 1 | 2023 | 6 | 0.220 |
Why?
|
Nutritional Status | 1 | 2023 | 30 | 0.220 |
Why?
|
Risk Factors | 7 | 2018 | 3325 | 0.220 |
Why?
|
Practice Guidelines as Topic | 4 | 2019 | 318 | 0.220 |
Why?
|
Back Pain | 1 | 2023 | 33 | 0.210 |
Why?
|
Cost Sharing | 1 | 2023 | 30 | 0.210 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2005 | 375 | 0.200 |
Why?
|
Risk Assessment | 4 | 2019 | 1097 | 0.200 |
Why?
|
Depressive Disorder, Major | 1 | 2023 | 124 | 0.200 |
Why?
|
Public Health | 1 | 2022 | 80 | 0.200 |
Why?
|
Health Status Disparities | 2 | 2020 | 146 | 0.190 |
Why?
|
Adrenergic alpha-Antagonists | 2 | 2018 | 9 | 0.190 |
Why?
|
Counseling | 3 | 2019 | 189 | 0.190 |
Why?
|
Personnel Management | 1 | 2021 | 3 | 0.190 |
Why?
|
Data Collection | 5 | 2013 | 256 | 0.190 |
Why?
|
Cancer Survivors | 1 | 2022 | 83 | 0.190 |
Why?
|
Cell Phone | 1 | 2021 | 12 | 0.190 |
Why?
|
Community-Based Participatory Research | 1 | 2021 | 60 | 0.190 |
Why?
|
Overweight | 1 | 2023 | 269 | 0.190 |
Why?
|
Evidence-Based Practice | 2 | 2021 | 46 | 0.190 |
Why?
|
Breast | 1 | 2021 | 84 | 0.190 |
Why?
|
Survivors | 3 | 2022 | 149 | 0.180 |
Why?
|
Nurse-Patient Relations | 1 | 2020 | 8 | 0.180 |
Why?
|
Organizational Culture | 1 | 2020 | 18 | 0.180 |
Why?
|
Adrenergic beta-Agonists | 1 | 2020 | 33 | 0.180 |
Why?
|
Workload | 1 | 2020 | 30 | 0.170 |
Why?
|
Diabetes Mellitus | 2 | 2018 | 487 | 0.170 |
Why?
|
Community Health Planning | 1 | 2019 | 19 | 0.170 |
Why?
|
Geography | 1 | 2019 | 39 | 0.170 |
Why?
|
Suicide | 1 | 2021 | 123 | 0.170 |
Why?
|
Neoplasm Grading | 2 | 2017 | 48 | 0.170 |
Why?
|
Health Expenditures | 2 | 2018 | 75 | 0.170 |
Why?
|
Text Messaging | 1 | 2020 | 29 | 0.170 |
Why?
|
Tobacco Use Cessation | 1 | 2019 | 22 | 0.170 |
Why?
|
Health Plan Implementation | 1 | 2019 | 36 | 0.170 |
Why?
|
Benzodiazepines | 1 | 2019 | 27 | 0.170 |
Why?
|
Administration, Oral | 1 | 2019 | 85 | 0.170 |
Why?
|
Sex Factors | 2 | 2019 | 643 | 0.170 |
Why?
|
Communication | 1 | 2021 | 194 | 0.170 |
Why?
|
Lung Diseases, Interstitial | 1 | 2019 | 5 | 0.170 |
Why?
|
Sleep Wake Disorders | 1 | 2019 | 37 | 0.170 |
Why?
|
Outcome and Process Assessment (Health Care) | 2 | 2010 | 102 | 0.160 |
Why?
|
Motivation | 1 | 2020 | 130 | 0.160 |
Why?
|
Anxiety Disorders | 1 | 2019 | 91 | 0.160 |
Why?
|
Child | 6 | 2024 | 2474 | 0.160 |
Why?
|
Palliative Care | 1 | 2019 | 57 | 0.160 |
Why?
|
Health Services Research | 4 | 2016 | 231 | 0.160 |
Why?
|
Suicide, Attempted | 1 | 2020 | 96 | 0.160 |
Why?
|
Suicidal Ideation | 1 | 2020 | 100 | 0.160 |
Why?
|
Health Facilities | 1 | 2018 | 17 | 0.160 |
Why?
|
Mortality | 1 | 2019 | 117 | 0.160 |
Why?
|
Patients | 1 | 2018 | 34 | 0.160 |
Why?
|
Hypertension | 2 | 2013 | 500 | 0.150 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 145 | 0.150 |
Why?
|
Surveys and Questionnaires | 5 | 2021 | 1309 | 0.150 |
Why?
|
Office Visits | 2 | 2014 | 80 | 0.140 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 243 | 0.140 |
Why?
|
Outcome Assessment (Health Care) | 1 | 2017 | 228 | 0.130 |
Why?
|
Odds Ratio | 3 | 2017 | 671 | 0.130 |
Why?
|
Mental Health | 2 | 2014 | 165 | 0.130 |
Why?
|
Comorbidity | 2 | 2009 | 594 | 0.130 |
Why?
|
Quality of Life | 1 | 2019 | 507 | 0.130 |
Why?
|
Comparative Effectiveness Research | 2 | 2013 | 66 | 0.130 |
Why?
|
Telephone | 3 | 2012 | 161 | 0.120 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 6 | 0.120 |
Why?
|
Reminder Systems | 1 | 2015 | 80 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2014 | 47 | 0.120 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 28 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2014 | 70 | 0.120 |
Why?
|
Heart Failure | 1 | 2019 | 396 | 0.110 |
Why?
|
Medical Record Linkage | 1 | 2013 | 38 | 0.110 |
Why?
|
Physicians | 2 | 2005 | 137 | 0.110 |
Why?
|
Episode of Care | 1 | 2013 | 14 | 0.110 |
Why?
|
Patient Satisfaction | 2 | 2023 | 211 | 0.110 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2013 | 57 | 0.110 |
Why?
|
Medicare Part C | 1 | 2013 | 19 | 0.110 |
Why?
|
Papillomavirus Vaccines | 1 | 2014 | 113 | 0.100 |
Why?
|
Hospitalization | 3 | 2015 | 797 | 0.100 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 31 | 0.100 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2012 | 10 | 0.100 |
Why?
|
Pilot Projects | 2 | 2022 | 218 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 133 | 0.100 |
Why?
|
Vulnerable Populations | 1 | 2012 | 39 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2012 | 230 | 0.100 |
Why?
|
Mental Disorders | 1 | 2014 | 280 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 52 | 0.090 |
Why?
|
Cluster Analysis | 3 | 2013 | 89 | 0.090 |
Why?
|
Outpatients | 1 | 2012 | 107 | 0.090 |
Why?
|
Longitudinal Studies | 1 | 2013 | 710 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2013 | 197 | 0.090 |
Why?
|
Chronic Disease | 2 | 2019 | 428 | 0.090 |
Why?
|
Glycated Hemoglobin A | 1 | 2011 | 216 | 0.090 |
Why?
|
Names | 1 | 2010 | 1 | 0.090 |
Why?
|
Social Support | 1 | 2011 | 203 | 0.090 |
Why?
|
Menu Planning | 1 | 2009 | 2 | 0.090 |
Why?
|
Education, Nonprofessional | 1 | 2009 | 6 | 0.090 |
Why?
|
Diagnosis-Related Groups | 1 | 2009 | 24 | 0.080 |
Why?
|
Sex Characteristics | 1 | 2009 | 69 | 0.080 |
Why?
|
Ovarian Neoplasms | 1 | 2009 | 49 | 0.080 |
Why?
|
Patient Admission | 1 | 2009 | 72 | 0.080 |
Why?
|
Pain Management | 1 | 2009 | 58 | 0.080 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2020 | 16 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2019 | 1115 | 0.080 |
Why?
|
Periodicals as Topic | 1 | 2009 | 14 | 0.080 |
Why?
|
Directive Counseling | 1 | 2009 | 25 | 0.080 |
Why?
|
Pain | 1 | 2009 | 79 | 0.080 |
Why?
|
Genes, BRCA1 | 2 | 2005 | 8 | 0.080 |
Why?
|
Genes, BRCA2 | 2 | 2005 | 8 | 0.080 |
Why?
|
Continental Population Groups | 1 | 2009 | 302 | 0.070 |
Why?
|
Mediterranean Region | 1 | 2006 | 1 | 0.070 |
Why?
|
Educational Measurement | 1 | 2006 | 18 | 0.070 |
Why?
|
Decision Making | 2 | 2005 | 183 | 0.070 |
Why?
|
Analgesics | 1 | 2006 | 27 | 0.070 |
Why?
|
Sex Distribution | 1 | 2006 | 190 | 0.070 |
Why?
|
Age Distribution | 1 | 2006 | 246 | 0.070 |
Why?
|
Anthrax | 1 | 2005 | 2 | 0.060 |
Why?
|
Organizations, Nonprofit | 1 | 2005 | 11 | 0.060 |
Why?
|
Influenza A virus | 1 | 2005 | 13 | 0.060 |
Why?
|
Postmenopause | 1 | 2006 | 241 | 0.060 |
Why?
|
Vaccines, Attenuated | 1 | 2005 | 45 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2005 | 70 | 0.060 |
Why?
|
International Classification of Diseases | 2 | 2020 | 85 | 0.060 |
Why?
|
Health Resources | 2 | 2013 | 37 | 0.060 |
Why?
|
Oregon | 2 | 2017 | 171 | 0.060 |
Why?
|
Pregnancy | 1 | 2010 | 1494 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2005 | 130 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 709 | 0.060 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2004 | 6 | 0.060 |
Why?
|
Reimbursement Mechanisms | 1 | 2004 | 20 | 0.060 |
Why?
|
Specialization | 1 | 2004 | 24 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2004 | 16 | 0.060 |
Why?
|
Smoking Prevention | 1 | 2004 | 54 | 0.060 |
Why?
|
Feasibility Studies | 2 | 2014 | 114 | 0.060 |
Why?
|
Infant | 2 | 2005 | 1171 | 0.060 |
Why?
|
Disease Notification | 1 | 2003 | 7 | 0.060 |
Why?
|
Georgia | 1 | 2023 | 26 | 0.050 |
Why?
|
Child, Preschool | 2 | 2005 | 1409 | 0.050 |
Why?
|
Urban Population | 1 | 2003 | 116 | 0.050 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 69 | 0.050 |
Why?
|
Survivorship | 1 | 2022 | 9 | 0.050 |
Why?
|
Logistic Models | 3 | 2017 | 926 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2022 | 75 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 212 | 0.050 |
Why?
|
Research | 1 | 2022 | 64 | 0.050 |
Why?
|
Mammography | 2 | 2014 | 169 | 0.050 |
Why?
|
Interviews as Topic | 2 | 2014 | 305 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2022 | 844 | 0.040 |
Why?
|
Advance Care Planning | 1 | 2019 | 12 | 0.040 |
Why?
|
Occult Blood | 1 | 2020 | 153 | 0.040 |
Why?
|
Prospective Studies | 1 | 2022 | 1267 | 0.040 |
Why?
|
Qualitative Research | 1 | 2020 | 254 | 0.040 |
Why?
|
Self Efficacy | 2 | 2009 | 68 | 0.040 |
Why?
|
Patient Care Team | 1 | 2019 | 113 | 0.040 |
Why?
|
Neoplasms, Second Primary | 1 | 2018 | 29 | 0.040 |
Why?
|
Depression | 1 | 2023 | 502 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2018 | 114 | 0.040 |
Why?
|
Cause of Death | 1 | 2018 | 181 | 0.040 |
Why?
|
Utilization Review | 1 | 1997 | 53 | 0.040 |
Why?
|
Medically Uninsured | 1 | 1997 | 44 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2018 | 172 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 103 | 0.030 |
Why?
|
Quality Improvement | 1 | 2017 | 189 | 0.030 |
Why?
|
Risk | 1 | 2017 | 516 | 0.030 |
Why?
|
Tobacco | 2 | 2005 | 14 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2014 | 11 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 129 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2013 | 22 | 0.030 |
Why?
|
Regression Analysis | 1 | 2014 | 297 | 0.030 |
Why?
|
Michigan | 1 | 2013 | 26 | 0.030 |
Why?
|
Europe | 1 | 2013 | 42 | 0.030 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 119 | 0.030 |
Why?
|
Survival Analysis | 1 | 2013 | 215 | 0.030 |
Why?
|
Physical Examination | 1 | 2012 | 20 | 0.030 |
Why?
|
Washington | 1 | 2013 | 374 | 0.020 |
Why?
|
Self Report | 1 | 2013 | 251 | 0.020 |
Why?
|
Warfarin | 1 | 2012 | 74 | 0.020 |
Why?
|
Blood Pressure | 1 | 2012 | 298 | 0.020 |
Why?
|
Current Procedural Terminology | 1 | 2009 | 3 | 0.020 |
Why?
|
Vaccination | 1 | 2014 | 635 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2012 | 330 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2009 | 237 | 0.020 |
Why?
|
Carbon Monoxide | 1 | 2009 | 13 | 0.020 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2009 | 7 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 304 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2010 | 166 | 0.020 |
Why?
|
Patient Participation | 1 | 2010 | 133 | 0.020 |
Why?
|
Social Environment | 1 | 2008 | 88 | 0.020 |
Why?
|
Biomarkers | 1 | 2009 | 301 | 0.020 |
Why?
|
Epidemiologic Measurements | 1 | 2005 | 1 | 0.020 |
Why?
|
Space-Time Clustering | 1 | 2005 | 3 | 0.020 |
Why?
|
Minnesota | 1 | 2005 | 53 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2005 | 88 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2005 | 185 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2005 | 368 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 1997 | 568 | 0.010 |
Why?
|
Health Status | 1 | 1997 | 298 | 0.010 |
Why?
|